CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a ...

CARMAT: Aeson® total artificial heart highlighted as a very promising solution for heart failure patients with pulmonary hypertension in The Journal of Heart and Lung Transplantation ...

More than 100 healthcare professionals from 41 hospitals and 10 countries rallied to share their experiences of the Aeson® artificial heart PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT ...

The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure ...

The Aeson device is designed to solve the limitations of current left-ventricular assist devices (LVAD), which pump blood in just one chamber, by pumping blood in both heart chambers.

Now a team of surgeons has successfully completed the first human implantation in the US of an artificial heart device called the 'Aeson', developed by French company CARMAT. The artificial heart has ...

Aeson Power takes pride in being the exclusive supplier for government departments and large enterprises in the Australian market. Specialising in high-reliability solar storage systems, battery ...

Following the Aeson® implant, all three patients experienced improved functional capacity, as demonstrated by 6-minute walk distances test, and were discharged from hospital on the Aeson ...

In December 2020, Aeson® had obtained CE marking in the bridge to transplant indication, under the Medical Device Directive (MDD), which was in force at the time. Since then, the MDD has been ...